نتایج جستجو برای: atenolol

تعداد نتایج: 2057  

Journal: :iranian chemical communication 0
masoumeh taei department of chemistry, payame noor university, pb box 19395-4697 tehran, iran foroozan hasanpour department of chemistry, payame noor university, pb box 19395-4697 tehran, iran marjan shavakhi 1department of chemistry, payame noor university, pb box 19395-4697 tehran, iran

a carbon-paste electrode (cpe) chemically modified with the n-4,4'-azodianiline(ferrocenyl schiff base) complex and multi wall carbon nanotubes (adafcnte) was used as a highly sensitive electrochemical sensor for determination of trace amounts of atenolol. the oxidation peak potentials in cyclic voltammogram of adafcnte occurred around 550 mv vs ag/agcl (at ph 6.0) while this peak potentia...

A carbon-paste electrode (CPE) chemically modified with the N-4,4'-azodianiline(ferrocenyl Schiff base) complex and multi wall carbon nanotubes (ADAFCNTE) was used as a highly sensitive electrochemical sensor for determination of trace amounts of atenolol. The oxidation peak potentials in cyclic voltammogram of ADAFCNTE occurred around 550 mV vs Ag/AgCl (at pH 6.0) while this peak potential at ...

Gholamreza Yarmohammadi Soghra Khabnadideh, Soliman Mohammadi Samani Zahra Rezaei,

       Propranolol, a prototypical b-adrenergic receptor antagonist and atenolol, a cardio-selective b-antagonist are widely used in therapeutic regimens for treatment of hypertensive patients. In Iran, several pharmaceutical manufacturers formulate these two b-blockers. As the formulation of a dosage form is essential for the patient's safety and drug efficacy, in this study we aimed to evalu...

Journal: :Clinical science and molecular medicine. Supplement 1976
L Hansson B E Karlberg H Aberg A Westerlund N C Henningsen S Jameson

1. Atenolol (ICI 66.082, Tenormin) is a new beta-adrenoreceptor-blocking agent, devoid of intrinsic sympathomimetic and membrane-stabilizing properties. It does not cross the blood-brain barrier. 2. Atenolol given to hypertensive patients in initial open trials reduced arterial blood pressure significantly. 3. A double-blind comparison between atenolol and placebo in forty-five patients with es...

2012
P.

1. Nineteen healthy men aged 50 years, with untreated, mild essential hypertension WHO group I, were randomized into two groups to study the effect of treatment (18 weeks) with oxprenolol (n = 10) and atenolol (n = 9) on serum cholesterol fractions, total triglycerides and uric acid. 2. Oxprenolol lowered high density lipoprotein (HDL) cholesterol by 11.4% (P < 0.02) and cholesterol ratio (HDL ...

2005
Brian D. Guth Gerd Heusch Rainald Seitelberger John Ross

We examined the importance of decreased heart rate in the beneficial effect of/3-adrenergic blockade on exercise-induced regional myocardial ischemia and contractile dysfunction in conscious dogs with single vessel coronary stenosis (ameroid constrictor). Studies were performed during control treadmill exercise, which produced regional myocardial ischemia (blood flow measured with microspheres)...

Journal: :American journal of therapeutics 2010
Anil Pareek Harsha Salkar Pradeep Mulay Shubha Desai Nitin Chandurkar Neelam Redkar

As there is a strong, positive, and continuous correlation between blood pressure and risk of cardiovascular diseases; improved control of blood pressure is necessary to produce maximum reduction in clinical cardiovascular endpoints. The primary objective was to demonstrate that atenolol/amlodipine combination therapy is superior to atenolol monotherapy with respect to mean fall in systolic blo...

Journal: :Chest 1985
A B Montgomery M A Stager R B Schoene

We describe a patient who ingested 5 g of atenolol with ethanol. After awakening, with repeat toxicology screen only showing atenolol, and in spite of normal voluntary breathing mechanics, he had marked suppression of his spontaneous respirations as measured by minute ventilation and by occlusion pressure with no incremental response to hypercapnic challenge. Subsequently, he recovered. Althoug...

Journal: :American journal of hypertension 2006
Zahid Dhakam Carmel M McEniery Yasmin John R Cockcroft Morris J Brown Ian B Wilkinson

BACKGROUND Recent data suggest that atenolol may be inferior to other antihypertensive drugs in reducing cardiovascular risk in older individuals with hypertension, despite lowering peripheral blood pressure (BP). We hypothesized that that atenolol fails to reduce central BP as much as other agents. The aim of the present study was to compare the hemodynamic effects of atenolol and eprosartan i...

Journal: :PLoS Biology 2006
Gavin Yamey

Background: A recent meta-analysis of drug effects in patients with hypertension claims that all β-adrenergic blockers are equally effective but less so than other antihypertensive drugs. Published comparisons of the β-adrenergic blocker atenolol and non-atenolol β-adrenergic blockers indicate different effects on death rates, arrhythmias, peripheral vascular resistance and prognosis post myoca...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید